102
Participants
Start Date
January 1, 2005
Primary Completion Date
June 1, 2008
Study Completion Date
December 1, 2008
romidepsin (depsipeptide, FK228)
Study patients received romidepsin at a dose of 14 mg/m\^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
University of Pennsylvania Abrahamson Cancer Center, Philadelphia
Vanderbilt-Ingram Cancer Center, Nashville
MD Anderson Cancer Center, Houston
UCLA Jonsson Cancer Center, Los Angeles
Stanford Comprehensive Cancer Center, Stanford
Boston Medical Center, Boston
Research Site, Multiple Locations
Research Site, Multiple Locations
Research Site, Multiple Locations
Research Site, Multiple Locations
Research Site, Multiple Locations
Lead Sponsor
Collaborators (1)
Celgene Corporation
INDUSTRY
Celgene
INDUSTRY